drugset / Trial / NCT03330171

Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine

NCT03330171

Phase 4 Unknown 278 enrolled University of Witwatersrand, South Africa
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This trial will evaluate the safety and immunogenicity of: i) measles vaccine (CAM-70) after primary dose at 6 months (MV1) and booster vaccination at 12 months (MV2); ii) a single dose of varicella vaccination at 18 months; and iii) a single dose of hepatitis-A vaccination at 18 months in HIV-exposed and HIV-unexposed South African children.

Timeline

Start
2017-04-10
Primary completion
2019-02-26
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Havrix Vaccine 0.5 ml Intramuscular
Subject Measles vaccine Vaccine 0.5 ml Subcutaneous
Subject Varicella vaccine Vaccine 0.5 ml Subcutaneous